Bone Marrow Diseases News

Bone Marrow Diseases	Welcome, Profile Billing Logout

«1 2...41 42 43 44 45 46 47 48 49 50 51 5253

||||||||||  danazol oral / Generic mfg.
New P1/2 trial:  Danazol for Genetic Bone Marrow and Lung Disorders (clinicaltrials.gov) -  Sep 25, 2011
P1/2, N=35, Recruiting,  Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

||||||||||  Promacta (eltrombopag) / Novartis
New P2 trial:  ASPIRE: A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (clinicaltrials.gov) -  Sep 22, 2011
P2, N=150, Recruiting,  Sponsor: GlaxoSmithKline

||||||||||  Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment closed:  Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome (clinicaltrials.gov) -  Sep 22, 2011
P1, N=102, Active, not recruiting,  Sponsor: Onconova Therapeutics, Inc.
Recruiting --> Active, not recruiting

||||||||||  Synribo (omacetaxine mepesuccinate) / Teva
Enrollment change:  Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) -  Sep 19, 2011
P2, N=60, Recruiting,  Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=20 --> 60

||||||||||  Inrebic (fedratinib) / BMS
New P3 trial:  Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (clinicaltrials.gov) -  Sep 19, 2011
P3, N=225, Active, not recruiting,  Sponsor: Sanofi

||||||||||  Cytovene (ganciclovir) / Roche
Trial completion:  Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant (clinicaltrials.gov) -  Sep 19, 2011
P2, N=61, Completed,  Sponsor: City of Hope Medical Center
N=20 --> 60 Active, not recruiting --> Completed

||||||||||  clofarabine / Generic mfg.
Enrollment closed:  Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) -  Sep 18, 2011
P1/2, N=27, Active, not recruiting,  Sponsor: University of Utah
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion:  Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies (clinicaltrials.gov) -  Sep 18, 2011
P2, N=47, Completed,  Sponsor: University of Utah
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Vonjo (pacritinib) / SOBI
New P2 trial:  SB1518 for Patients With Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) -  Sep 15, 2011
P2, N=8, Terminated,  Sponsor: M.D. Anderson Cancer Center

|||||||||| Enrollment open: Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) (clinicaltrials.gov) - Sep 14, 2011
P1, N=34, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  deferasirox tablet for oral suspension / Generic mfg.
Trial completion:  Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload (clinicaltrials.gov) -  Sep 8, 2011
P4, N=309, Completed,  Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

||||||||||  gandotinib (LY 2784544) / Eli Lilly
Enrollment change:  A Study in Myeloproliferative Disorders (clinicaltrials.gov) -  Sep 6, 2011
P1, N=80, Active, not recruiting,  Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed N=60 --> 80

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, IO biomarker:  Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) -  Sep 1, 2011
P2, N=48, Active, not recruiting,  Sponsor: Barbara Ann Karmanos Cancer Institute
N=60 --> 80 Recruiting --> Active, not recruiting

||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
New P2 trial, Metastases:  Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone (clinicaltrials.gov) -  Aug 31, 2011
P2, N=46, Recruiting,  Sponsor: David C Smith

|||||||||| New P2 trial, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 31, 2011
P2, N=42, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center

||||||||||  imatinib / Generic mfg., dasatinib / Generic mfg.
Enrollment closed:  NordCML006: Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia (clinicaltrials.gov) -  Aug 31, 2011
P2, N=40, Active, not recruiting,  Sponsor: Norwegian University of Science and Technology
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  imatinib / Generic mfg., dasatinib / Generic mfg.
New P1 trial:  Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate (clinicaltrials.gov) -  Aug 29, 2011
P1, N=4, Terminated,  Sponsor: National Cancer Institute (NCI)

||||||||||  OPB-31121 / Otsuka
Trial termination, Metastases:  Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes (clinicaltrials.gov) -  Aug 24, 2011
P1, N=6, Terminated,  Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Colloborator-Sponsor decision to terminate.

||||||||||  OPB-31121 / Otsuka
Enrollment change, Metastases:  Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes (clinicaltrials.gov) -  Aug 24, 2011
P1, N=6, Terminated,  Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Terminated; Colloborator-Sponsor decision to terminate. N=48 --> 6

||||||||||  Ojjaara (momelotinib) / GSK
New P1/2 trial, IO biomarker:  Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) -  Aug 23, 2011
P1/2, N=61, Active, not recruiting,  Sponsor: Gilead Sciences

||||||||||  Targretin oral (bexarotene oral) / ReXceptor, Leukine (sargramostim) / Partner Therap
Enrollment closed:  Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) -  Aug 23, 2011
P2, N=26, Active, not recruiting,  Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=48 --> 6 Recruiting --> Active, not recruiting

||||||||||  Telintra (ezatiostat) / MabVax
New P2 trial:  Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome (clinicaltrials.gov) -  Aug 22, 2011
P2, N=2, Terminated,  Sponsor: Telik

||||||||||  lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion:  Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis (clinicaltrials.gov) -  Aug 22, 2011
P2, N=39, Completed,  Sponsor: Cephalon
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  clofarabine / Generic mfg.
New P1/2 trial:  Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) (clinicaltrials.gov) -  Aug 21, 2011
P1/2, N=20, Recruiting,  Sponsor: University Hospital Southampton NHS Foundation Trust.

||||||||||  Inrebic (fedratinib) / BMS
New P2 trial:  Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia (clinicaltrials.gov) -  Aug 18, 2011
P2, N=90, Active, not recruiting,  Sponsor: Sanofi

||||||||||  Inrebic (fedratinib) / BMS
New P2 trial:  Phase 2 Study of SAR302503 in Patients With Myelofibrosis (clinicaltrials.gov) -  Aug 18, 2011
P2, N=30, Active, not recruiting,  Sponsor: Sanofi

||||||||||  Bosulif (bosutinib) / Pfizer
Enrollment closed:  B1871006: Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias (clinicaltrials.gov) -  Aug 18, 2011
P1/2, N=571, Active, not recruiting,  Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Telintra (ezatiostat) / MabVax
Trial completion:  Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) -  Aug 16, 2011
P2, N=86, Completed,  Sponsor: Telik
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  azacitidine / Generic mfg.
Enrollment closed, Pre-transplantation:  5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome (clinicaltrials.gov) -  Aug 15, 2011
P2, N=75, Active, not recruiting,  Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination:  FB-ATG: Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin (clinicaltrials.gov) -  Aug 15, 2011
P2, N=20, Terminated,  Sponsor: King's College Hospital NHS Trust
Recruiting --> Active, not recruiting Recruiting --> Terminated; FB ATG is now a standard for sib allo MDS patients

||||||||||  hydroxychloroquine / Generic mfg.
New P1 trial:  Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases (clinicaltrials.gov) -  Aug 14, 2011
P1, N=24, Recruiting,  Sponsor: Virginia Commonwealth University

|||||||||| Enrollment closed: American Ginseng in Treating Patients With Fatigue Caused by Cancer (clinicaltrials.gov) - Aug 9, 2011
P3, N=360, Active, not recruiting, Sponsor: North Central Cancer Treatment Group
Recruiting --> Terminated; FB ATG is now a standard for sib allo MDS patients Recruiting --> Active, not recruiting

||||||||||  balixafortide (POL 6326) / Spexis
New P1/2 trial, Metastases:  Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (clinicaltrials.gov) -  Aug 8, 2011
P1/2, N=60, Recruiting,  Sponsor: Polyphor Ltd.

|||||||||| Enrollment change: The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=10, Completed, Sponsor: University of Utah
Recruiting --> Active, not recruiting N=20 --> 10

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical:  Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome (clinicaltrials.gov) -  Aug 7, 2011
P2, N=53, Completed,  Sponsor: M.D. Anderson Cancer Center
N=20 --> 10 Active, not recruiting --> Completed

|||||||||| Trial completion: The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=10, Completed, Sponsor: University of Utah
Active, not recruiting --> Completed Recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites